Ginkgo Results Presentation Deck

Ginkgo is in a stronger position now vs. any time in our history Strong Financial Health Strong performance: exceeded all of our public KPIs in 2021 Long runway: ended the year with over $1.5 billion in cash, providing meaningful multi-year runway as we drive towards profitability Diversified Customer Base Healthy mix of programs across all axes Individual end-markets can come in and out of favor (e.g., biofuels); diversification insulates us from these dynamics New Business Running at Scale in Biosecurity New Programs Strategic Position Strengthened 30 7 23 Outlook Program Segmentation 31 31 Actuals Mature 35% Customer Size Mid-stage 25% Foundry Revenue $100+ $100+ Outlook Early-stage 40% $113 $113 Actuals Biosecurity Revenue $201 Third Party 46% $110+ $60 $50 Outlook Partnership Type Structured Partnership 23% Platform Venture 31% $201 Actuals Industry Govt. 7% Pharma & Biotech 25% Current market environment will benefit well-capitalized industry leaders Opportunity to continue long-term scaling plans (while narrow competitors may need to focus on nearer-term opportunities), including platform investments and M&A Scaled business from $17 million to $201 million of profitable revenue in one year Established credibility as a leading provider of K-12 testing and are now working with the public sector to help define what a stable biosecurity infrastructure needs to look like Food & Ag. 30% Cons. & Tech 14% Preliminary Outlook Revised Outlook Actuals Ind. & Environ. 24% 16 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW

View entire presentation